FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |  |
|-------------|------|-------|--|
|             |      |       |  |

| <b>STATEMENT</b> | <b>OF CHANGES</b> | IN BENEFICIAL | <b>OWNERSHIP</b> |
|------------------|-------------------|---------------|------------------|
|                  |                   |               |                  |

| OMB APPR                 | OMB APPROVAL |  |  |  |  |  |  |  |
|--------------------------|--------------|--|--|--|--|--|--|--|
| OMB Number: 3235-03      |              |  |  |  |  |  |  |  |
| Estimated average burden |              |  |  |  |  |  |  |  |
| hours per response:      | 0.5          |  |  |  |  |  |  |  |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Lamothe Jeffrey G.                     |       |   |                        | 2. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [ APVO ] |  |          |  |                          |   | (Ch  | eck all applic<br>Directo                           | able)   | Person(s) to Iss<br>10% Ov<br>Other (s                            | vner   |  |
|--|-------|---|------------------------|---|--|----------|--|--------------------------|---|--|---|---|---|--|--|
| (Last) (First) (Middle) C/O APTEVO THERAPEUTICS INC. 2401 4TH AVENUE, SUITE 1050 |       |   |                        |   | 3. Date of Earliest Transaction (Month/Day/Year) 03/04/2022                                |          |  |                          |   |  |   | A below)  | CF  | below)   |  |
| (Street) SEATTL (City)   | E W   | Ά   | 98121<br>(Zip)         | 4.  | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                   |          |  |                          | Line  | Individual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |   |   |   |  |  |
|  |       | Tab   | le I - Non-D           | erivativ  | e Se   | curities | s Acc  | quired, Di               | sposed o  | f, or Be   | neficiall   | y Owned   |   |  |  |
| Date   |       | Transactior<br>te<br>onth/Day/Y                           | Execution Date,        |   | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5) |          | ed (A) or<br>tr. 3, 4 and                                      |                          | s Fo<br>ally (D)<br>following (I)   | Form: Direct   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |   |   |  |  |
|  |       |   |                        |   |  | Code V   | Amount   | (A) or<br>(D)            | Price   | Reported<br>Transact<br>(Instr. 3 a  | ion(s)  |   | (Instr. 4)  |  |  |
|  |       | -   | Table II - Der<br>(e.ç |   |  |          |  | uired, Dis<br>, options, |   |  | ,   | Owned   |   |  |  |
| Derivative Conversion Date Ex<br>Security Or Exercise (Month/Day/Year) if a      |       | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Yea | Code (Instr.           |   | n of   |          | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                          | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s<br>(Instr. 4) | Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |       |   |                        |   | v  | (A)      | (D)  | Date<br>Exercisable      | Expiration<br>Date  | Title  | Amount<br>or<br>Number<br>of<br>Shares              |   |   |  |  |
| Stock<br>Option<br>(right to<br>buy)   | \$5.3 | 03/04/2022  |                        | A   |  | 11,000   |  | (1)                      | 03/03/2032  | Common<br>Stock  | 11,000  | \$0.00  | 11,000  | D  |  |

## Explanation of Responses:

1. The option vests in three approximately equal annual installments beginning on March 3, 2023.

## Remarks:

/s/ SoYoung Kwon, attorney-in-03/04/2022 fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints SoYoung Kwon and Daphne Taylor as his or her true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Aptevo Therapeutics Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder, and any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report, and timely file such form or report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his or her discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Securities Exchange Act of 1934 and the rules thereunder, as amended.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of February, 2022.

/s/ Jeffrey G. Lamothe